Fulcrum Therapeutics Inc (FULC) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $8.73
• Market Cap: $592.41M
• EPS: $-1.14
• 52-Week High: $15.74
• 52-Week Low: $2.31

Market Sentiment

Fulcrum Therapeutics Inc currently has a Bullish sentiment score of 0.24.

About Fulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapies for genetically defined diseases with pressing unmet medical needs. The company boasts a robust pipeline, particularly targeting conditions like Duchenne Muscular Dystrophy, and is committed to transforming patient care through precision medicine. Leveraging its proprietary drug discovery platform, Fulcrum is strategically positioned to not onl...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Fulcrum Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does FULC pay dividends?

Fulcrum Therapeutics Inc (FULC) does not currently pay a regular dividend.

What is FULC's market cap?

Fulcrum Therapeutics Inc (FULC) has a market capitalization of $592.41M with a current stock price of $8.73.